They may regain weight, see a slowdown in their weight loss or develop new side effects
The exceptional efficacy of Ozempic led to the FDA approval of a higher-dose formulation specifically designed to treat obesity, marketed under the brand name Wegovy
Disclosures: Melissa Kaltenbach: Nothing to Disclose, David Kaplan: AstraZeneca Inc: Grant/Research Support, Roche Genentech: Independent Contractor, Exact Sciences: Grant/Research Support, Glycotest: Grant/Research Support, Sirtex: Advisor, Exelixis: Advisor, AstraZeneca: Advisor, Marina Serper: Transplant Genomics: Grant/Research Support, Grifols: Grant/Research Support, Eurofins: Grant/Research Support, Therese Bittermann: Nothing to Disclose 2218 DIGITAL PHENOTYPE VARIES BY ALCOHOL USE HISTORY AND HEPATIC ENCEPHALOPATHY Jessica Mellinger 1 Tingting Liu 2 Haila Asefa 3 Patricia Bloom 4 Sal Giorgi 2 Brenda Curtis 5 , 1 University of Michigan Hospitals and Health Centers, 2 Technology and Translational Research Unit, National Institute on Drug Abuse, 3 University of Michigan Hospitals and Health Center, 4 University of Michigan, Michigan Medicine, 5 National Institutes of Health Background: Hepatic encephalopathy (HE) is responsible for substantial cirrhosis-related burden and may be detectable by digital phenotyping
Understanding that obesity is a chronic disease helps frame realistic expectations about treatment duration
